Streetbeat News

Earnings

APG

APi Group has updated its Q1 2024 revenue forecast to $1.59B-$1.61B, from the previous range of $1.56B-$1.61B, with an estimated consensus at $1.592B. The company also adjusted its EBITDA forecast to $172-$177 million from the prior $165-$180 million, and expects adjusted free cash flow to be ahead of last year, aligning with seasonal cash flow trends.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 11:36 am

GS

Goldman Sachs shares are trading higher following the announcement of their Q1 earnings, which surpassed analysts' expectations in both EPS and revenues.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 11:34 am

GS

Goldman Sachs reported a Q1 provision for credit losses of $318M, a significant shift from a net benefit of $171M in the same quarter last year.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 11:32 am

GS

Goldman Sachs reported a 15% increase in Q1 Global Banking & Markets revenue year-over-year. This includes a 32% rise in Investment Banking revenues, a 10% increase in Fixed Income, Currency and Commodities revenues, and a 10% increase in Equities revenue.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 11:31 am

GS

Goldman Sachs Gr reported Q1 2024 GAAP EPS of $11.58, surpassing the $8.60 estimate, with sales of $14.210B also beating the $12.917B estimate, marking a 16.25% increase over the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 11:28 am

AAPL

CRM

GS

MTB

QQQ

SCHW

SPY

TSLA

U.S. stocks are poised for a rebound despite geopolitical tensions, with futures indicating a positive open. The SPDR S&P 500 ETF Trust and Invesco QQQ ETF saw premarket gains. Analysts highlight a buying opportunity in tech stocks, expecting a strong earnings season to drive growth. Tesla, Apple, and Salesforce faced premarket declines due to various concerns, while Goldman Sachs, M&T Bank, and Charles Schwab are set to report earnings. Economic data releases and Fed speakers are also in focus.

Portfolio Pulse from Shanthi Rexaline

April 15, 2024 | 11:27 am

EGRX

Eagle Pharmaceuticals announced it will present additional data from its Phase 3 trial on Amisulpride, a drug for postoperative nausea and vomiting, showing sustained response, at the ASPAN 2024 National Conference.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 11:25 am

UBX

Unity Biotechnology (NASDAQ:UBX) reported Q4 2023 GAAP EPS of $(0.28), surpassing the consensus estimate of $(0.77) by 63.64% and marking a 46.15% improvement over the previous year's $(0.52) per share loss.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 11:22 am

LUXH

LuxUrban Hotels (LUXH) projects Q1 2024 net rental revenue to be between $27M-$30M, below the consensus of $41.97M but up from $22.8M in Q1 2023. The company aims to enhance its portfolio with 3.5 to 4.5-star properties, increase TRevPAR and EBITDA, and improve working capital and cash flow by slowing acquisition pace and focusing on higher-end properties.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 11:14 am

LIFW

MSP Recovery reported a fiscal year adjusted EPS loss of $73.3 million, an increase from last year's $44.8 million loss. Sales decreased to $7.71 million from $23.42 million year-over-year.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 11:13 am